Century Therapeutics, Inc. (IPSC)
| Market Cap | 396.13M |
| Revenue (ttm) | 109.16M |
| Net Income (ttm) | -9.58M |
| Shares Out | 180.06M |
| EPS (ttm) | -0.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 543,982 |
| Open | 2.230 |
| Previous Close | 2.250 |
| Day's Range | 2.160 - 2.270 |
| 52-Week Range | 0.435 - 3.040 |
| Beta | 1.67 |
| Analysts | Strong Buy |
| Price Target | 4.25 (+93.18%) |
| Earnings Date | May 14, 2026 |
About IPSC
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoim... [Read more]
Financial Performance
In 2025, Century Therapeutics's revenue was $109.16 million, an increase of 1556.76% compared to the previous year's $6.59 million. Losses were -$9.58 million, -92.43% less than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for IPSC stock is "Strong Buy." The 12-month stock price target is $4.25, which is an increase of 93.18% from the latest price.
News
Century Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The company has pivoted its iPSC platform to focus on beta islet cell therapy for type 1 diabetes, targeting a large unmet need with a holistic immune evasion strategy and scalable manufacturing innovations. IND submission is planned for late 2025, with initial clinical data expected in 2027.
Century Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Two lead programs, CNTY-813 for Type 1 Diabetes and CNTY-308 for autoimmune diseases, are advancing toward clinical trials in 2024, both leveraging advanced immune evasion technology. Early clinical data for CNTY-813 are expected by 2027, with commercialization targeted for the early 2030s. Cash runway extends to Q1 2029.
Century Therapeutics to Participate in Upcoming Investor Conferences in March
PHILADELPHIA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for...
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
The iPSC-derived NK cells clinical trial analysis report delivers important insights into ongoing research of 15+ pipeline iPSC-derived NK cells drugs, clinical strategies, upcoming therapeutics, and ...
Century Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
The company is advancing iPSC-derived cell therapies for autoimmune diseases, cancer, and type 1 diabetes, with key programs moving toward clinical trials and IND submissions. Alloevasion technology enables immune evasion, supporting scalable therapies. Cash runway extends into Q4 2027.
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
PHILADELPHIA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for...
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for...
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes
PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for...
Century Therapeutics Transcript: Chardan’s 9th Annual Genetic Medicines Conference
Key programs in iPSC-derived NK and T cell therapies are advancing, with robust alloevasion technology enabling off-the-shelf treatments for autoimmune and B-cell diseases. Clinical and preclinical data show strong efficacy, safety, and persistence, with major data readouts expected this year.
Century Therapeutics to Present at Chardan's 9th Annual Genetic Medicines Conference
PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for...
Century Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Recent strategic transformation has prioritized high-potential iPSC-derived cell therapy programs, leveraging Allo-Evasion™ technology for both immune and non-immune targets. Century 101 is advancing in autoimmune disease trials, while Century 308 is set to enter the clinic next year.
Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell t...
Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Patient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated autoimmune diseases by year-end 2025 CNTY-308, a CAR-iT cell therapy functiona...
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress
PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell th...
Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
PHILADELPHIA, May 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell th...
Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting
PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell ...
Century Therapeutics Transcript: Status Update
Significant progress in iPSC-derived allogeneic cell therapies, with a reprioritized pipeline focused on transformative programs using advanced Allo-Evasion 5.0 technology. Manufacturing scalability and unique immune evasion features position the platform for broad clinical and commercial impact.
Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
PHILADELPHIA, March 19, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell ...
Century Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference
The company highlighted its iPSC platform's engineerability, reproducibility, and scalability, with promising phase 1 data for CNTY-101 in B-cell malignancies and expansion into autoimmune indications. Preclinical pipeline growth, new engineering advances, and a strong BMS partnership support a robust outlook.
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun...
Century Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference
The event highlighted advances in iPSC-derived cell therapies, emphasizing Allo-Evasion technology for improved persistence and safety. Interim phase 1 data in lymphoma showed strong safety and efficacy, while new trials target autoimmune diseases with flexible dosing and robust early endpoints.
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
– Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy –
Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference
PHILADELPHIA, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun...
Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer
- Morgan Conn, Ph.D., seasoned biotech executive with expertise in financing, business development, and corporate strategy, appointed as Chief Financial Officer -
Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
– Initiation of Phase 1 CALiPSO-1 Trial of CNTY-101 in Systemic Lupus Erythematosus, marking strategic expansion into autoimmune disease; protocol amended to include additional cohort of Lupus Nephrit...